Navigation Links
Effective ADHD treatment found for children with fragile X syndrome
Date:2/18/2008

Fragile X syndrome (FXS) is the most common hereditary form of mental retardation. Many children with FXS also suffer from attention deficit and/or hyperactivity disorder (ADHD), which complicates social relationships at home and at school. Although stimulant medication such as Ritalin is often successfully used to treat children with ADHD, studies have shown that while it is effective in children with mental retardation, it also causes side effects such as increased irritability, decreased verbalization and social withdrawal.

A previous study showed that L-acetyl carnitine (LAC), a form of the amino acid carnitine, significantly reduced hyperactive behavior in FXS boys with ADHD who were treated with it for one year without causing adverse side effects. The same authors have now conducted a randomized, double-blind, placebo-controlled multicenter study to determine the effectiveness of LAC in a larger group. The study is published in the April 1st, 2008 issue of the American Journal of Medical Genetics Part A, available online via Wiley InterScience at http://www3.interscience.wiley.com/cgi-bin/jhome/33129.

Led by M. Giulia Torrioli and Giovanni Neri of the Universit Cattolica in Rome, the study involved 51 boys between 6 and 12 years old with FXS and ADHD who were treated in one of eight centers in Italy, France and Spain. Each patient followed the treatment for 12 months, which involved 500 milligrams of LAC or a placebo given twice daily. Patients were evaluated by an interdisciplinary team of child neuropsychiatrists and psychologists at the start of the study, after one month, six months and 12 months. The effects of the drug and placebo were evaluated using a set of neuropsychological tests to assess behavior.

Those treated with LAC demonstrated reduced hyperactive behavior and increased attention. No side effects were exhibited, confirming that LAC is a safe alternative to stimulants. The patients treated with the placebo also showed reduced hyperactive behavior, although not nearly to the extent as the LAC-treated patients. The patients treated with LAC also had significantly improved social ability compared to the placebo-treated group. Both groups took intelligence tests, but LAC did not improve overall intellectual functioning.

We propose that LAC be recommended as a treatment of ADHD in FXS children, conclude the authors, since it effectively reduces hyperactive behavior and improves social abilities without adverse side effects. They also suggest that these results may be applicable to children with autism, who also do not easily tolerate stimulants.


'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
Source:Eurekalert

Related biology news :

1. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
2. Safe and effective therapy discovered for patients with protein-losing enteropathy
3. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
4. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
5. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
6. New hope for horse lovers as effective control for killer ragwort is proposed
7. Trial seeks genetic fingerprint for predicting drug effectiveness
8. MIT model could improve some drugs effectiveness
9. New nanoparticle vaccine is more effective but less expensive
10. Socioeconomic position associated with effectiveness of HIV drugs
11. UC health news: molecular pathway may predict chemotherapy effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology: